Hope on horizon for migraine sufferers

The long, painful headache for some migraine suffers could soon be over.

A simple but effective treatment for the debilitating condition is closer to being manufactured after Queensland researchers teamed with Indian life science company Avesthagen.

The collaboration will enable migraine genetics research by Queensland University of Technology's Genomics Research Centre to be used for the creation of a vitamin-B preventative therapy.

Professor Lyn Griffiths said the therapy would target a gene linked to aura, a debilitating type of migraine involving neurological disturbances and blurry vision.

"(It) affects about 30 per cent of migraine sufferers," Prof Griffiths said.

"And we found in two clinical trails that a specific combination of B vitamins could reduce the frequency and severity of migraine in these individuals."

Avesthagen executive chairman Dr Villoo Patell said the company was excited about providing a diagnosis and treatment for migraine sufferers.

The migraine diagnostic and targeted vitamin therapy will be launched in India, the Middle East and North Africa.